M. Fuertes

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 389 citations · Full text

Medicine, Hematology, Oncology +15

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

MV Mateos, Miguel‐Teodoro Hernández, Norma C. Gutiérrez et al. · Haematologica · 2008 · 88 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis

Fernando Ramos, Cristina Robledo, Francisco Miguel Izquierdo-García et al. · Oncotarget · 2016 · 49 citations · Full text

Medicine, Hematology, Oncology +12

Low expression of <i>ZHX2</i>, but not <i>RCBTB2</i> or <i>RAN</i>, is associated with poor outcome in multiple myeloma

Adriana Armellini, María Eugenia Sarasquete, Ramón García‐Sánz et al. · British Journal of Haematology · 2008 · 35 citations · Full text

Medicine, Cancer Biology, Oncology +15

Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine

María Abáigar, Fernando Ramos, Rocí­o Benito et al. · Annals of Hematology · 2013 · 18 citations

Medicine, Genetics, Oncology +17